Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Inhibition of Phosphoinositide-3-Kinase Signaling Promotes the Stem Cell State of Trophoblast.

Lee CQE, Bailey A, Lopez-Tello J, Sferruzzi-Perri AN, Okkenhaug K, Moffett A, Rossant J, Hemberger M.

Stem Cells. 2019 Jun 24. doi: 10.1002/stem.3052. [Epub ahead of print]

PMID:
31233251
2.

Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Lim EL, Okkenhaug K.

Immunology. 2019 Jul;157(3):210-218. doi: 10.1111/imm.13082. Review.

PMID:
31107985
3.

Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ.

Swan DJ, Aschenbrenner D, Lamb CA, Chakraborty K, Clark J, Pandey S, Engelhardt KR, Chen R, Cavounidis A, Ding Y, Krasnogor N, Carey CD, Acres M, Needham S, Cant AJ, Arkwright PD, Chandra A, Okkenhaug K, Uhlig HH, Hambleton S.

Haematologica. 2019 May 9. pii: haematol.2018.208397. doi: 10.3324/haematol.2018.208397. [Epub ahead of print]

4.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
5.

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.

Chellappa S, Kushekhar K, Munthe LA, Tjønnfjord GE, Aandahl EM, Okkenhaug K, Taskén K.

J Immunol. 2019 Mar 1;202(5):1397-1405. doi: 10.4049/jimmunol.1701703. Epub 2019 Jan 28.

PMID:
30692213
6.

PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner.

Stark AK, Chandra A, Chakraborty K, Alam R, Carbonaro V, Clark J, Sriskantharajah S, Bradley G, Richter AG, Banham-Hall E, Clatworthy MR, Nejentsev S, Hamblin JN, Hessel EM, Condliffe AM, Okkenhaug K.

Nat Commun. 2018 Aug 9;9(1):3174. doi: 10.1038/s41467-018-05674-8.

7.

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.

Gyori D, Lim EL, Grant FM, Spensberger D, Roychoudhuri R, Shuttleworth SJ, Okkenhaug K, Stephens LR, Hawkins PT.

JCI Insight. 2018 Jun 7;3(11). pii: 120631. doi: 10.1172/jci.insight.120631. eCollection 2018 Jun 7.

8.

Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.

Lim EL, Cugliandolo FM, Rosner DR, Gyori D, Roychoudhuri R, Okkenhaug K.

JCI Insight. 2018 Jun 7;3(11). pii: 120626. doi: 10.1172/jci.insight.120626. eCollection 2018 Jun 7.

9.

Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes.

Benson RA, Garcon F, Recino A, Ferdinand JR, Clatworthy MR, Waldmann H, Brewer JM, Okkenhaug K, Cooke A, Garside P, Wållberg M.

Front Immunol. 2018 May 18;9:1006. doi: 10.3389/fimmu.2018.01006. eCollection 2018.

10.

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM.

Immunity. 2018 Apr 17;48(4):831-832. doi: 10.1016/j.immuni.2018.03.034. No abstract available.

11.

PI3K induces B-cell development and regulates B cell identity.

Abdelrasoul H, Werner M, Setz CS, Okkenhaug K, Jumaa H.

Sci Rep. 2018 Jan 22;8(1):1327. doi: 10.1038/s41598-018-19460-5.

12.

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM.

Immunity. 2017 Nov 21;47(5):875-889.e10. doi: 10.1016/j.immuni.2017.10.017. Erratum in: Immunity. 2018 Apr 17;48(4):831-832.

13.

Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4+ T Cell Differentiation via PI3K p110δ-Akt-Mediated Signals.

Mauro C, Smith J, Cucchi D, Coe D, Fu H, Bonacina F, Baragetti A, Cermenati G, Caruso D, Mitro N, Catapano AL, Ammirati E, Longhi MP, Okkenhaug K, Norata GD, Marelli-Berg FM.

Cell Metab. 2017 Mar 7;25(3):593-609. doi: 10.1016/j.cmet.2017.01.008. Epub 2017 Feb 9.

14.

PI3Kδ and primary immunodeficiencies.

Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K.

Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12. Review.

15.

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Okkenhaug K, Graupera M, Vanhaesebroeck B.

Cancer Discov. 2016 Oct;6(10):1090-1105. Epub 2016 Sep 21. Review.

16.

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP.

Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14.

17.

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ.

J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.

18.

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.

Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, Fabozzi G, Shih HY, Kanno Y, Muto A, Zhu J, Gattinoni L, O'Shea JJ, Okkenhaug K, Igarashi K, Leonard WJ, Restifo NP.

Nat Immunol. 2016 Jul;17(7):851-860. doi: 10.1038/ni.3441. Epub 2016 May 9.

19.

Corrigendum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, Friedman L, Turner M, Okkenhaug K, Vanhaesebroeck B.

Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17641. Epub 2016 Apr 6. No abstract available.

PMID:
27049952
20.

Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.

Barbera Betancourt A, Emery JL, Recino A, Wong FS, Cooke A, Okkenhaug K, Wallberg M.

PLoS One. 2016 Jan 19;11(1):e0146516. doi: 10.1371/journal.pone.0146516. eCollection 2016.

21.

PI3Kδ promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1.

Garçon F, Okkenhaug K.

Immunol Cell Biol. 2016 May;94(5):486-95. doi: 10.1038/icb.2016.1. Epub 2016 Jan 7.

22.

The transcription factor BACH2 promotes tumor immunosuppression.

Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM, Yu Z, Mehta G, Liu H, Jin P, Ji Y, Palmer DC, Pan JH, Chichura A, Crompton JG, Patel SJ, Stroncek D, Wang E, Marincola FM, Okkenhaug K, Gattinoni L, Restifo NP.

J Clin Invest. 2016 Feb;126(2):599-604. doi: 10.1172/JCI82884. Epub 2016 Jan 5.

23.

Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Okkenhaug K, Burger JA.

Curr Top Microbiol Immunol. 2016;393:E1. doi: 10.1007/978-3-319-26133-1_482. No abstract available.

PMID:
29210027
24.

Oncogenic PI3Kα promotes multipotency in breast epithelial cells.

Okkenhaug K, Roychoudhuri R.

Sci Signal. 2015 Nov 3;8(401):pe3. doi: 10.1126/scisignal.aad5856. Review.

25.

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Okkenhaug K, Burger JA.

Curr Top Microbiol Immunol. 2016;393:123-142. doi: 10.1007/82_2015_484. Review.

26.

Editorial: Lipid Signaling in T Cell Development and Function.

Sauer K, Okkenhaug K.

Front Immunol. 2015 Aug 10;6:410. doi: 10.3389/fimmu.2015.00410. eCollection 2015. No abstract available.

27.

PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes.

Pearce VQ, Bouabe H, MacQueen AR, Carbonaro V, Okkenhaug K.

J Immunol. 2015 Oct 1;195(7):3206-17. doi: 10.4049/jimmunol.1501227. Epub 2015 Aug 26.

28.

Cowden's syndrome with immunodeficiency.

Browning MJ, Chandra A, Carbonaro V, Okkenhaug K, Barwell J.

J Med Genet. 2015 Dec;52(12):856-9. doi: 10.1136/jmedgenet-2015-103266. Epub 2015 Aug 5.

29.

PI3K inhibitors in inflammation, autoimmunity and cancer.

Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K.

Curr Opin Pharmacol. 2015 Aug;23:82-91. doi: 10.1016/j.coph.2015.05.017. Epub 2015 Jun 18. Review.

30.

Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation.

Doisne JM, Hüber CM, Okkenhaug K, Colucci F.

Cell Rep. 2015 Feb 10;10(5):702-710. doi: 10.1016/j.celrep.2015.01.002. Epub 2015 Feb 5.

31.

PI3K Signaling in B Cell and T Cell Biology.

Okkenhaug K, Turner M, Gold MR.

Front Immunol. 2014 Nov 3;5:557. doi: 10.3389/fimmu.2014.00557. eCollection 2014. No abstract available.

32.

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, Friedman L, Turner M, Okkenhaug K, Vanhaesebroeck B.

Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11. Erratum in: Nature. 2016 Jul 28;535(7613):580.

33.

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.

Burger JA, Okkenhaug K.

Nat Rev Clin Oncol. 2014 Apr;11(4):184-6. doi: 10.1038/nrclinonc.2014.42. Epub 2014 Mar 18. No abstract available.

34.

IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.

Attridge K, Kenefeck R, Wardzinski L, Qureshi OS, Wang CJ, Manzotti C, Okkenhaug K, Walker LS.

J Immunol. 2014 Mar 1;192(5):2195-201. doi: 10.4049/jimmunol.1302082. Epub 2014 Jan 27.

35.

Two birds with one stone: dual p110δ and p110γ inhibition.

Okkenhaug K.

Chem Biol. 2013 Nov 21;20(11):1309-10. doi: 10.1016/j.chembiol.2013.11.002.

36.

Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.

Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H, Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J, Kracker S, Debré M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M, Durandy A, Doffinger R, Chilvers ER, Cant AJ, Kumararatne D, Okkenhaug K, Williams RL, Condliffe A, Nejentsev S.

Science. 2013 Nov 15;342(6160):866-71. doi: 10.1126/science.1243292. Epub 2013 Oct 17.

37.

PI3K p110δ is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LTβR mRNA levels.

Zotes TM, Spada R, Mulens V, Pérez-Yagüe S, Sorzano CO, Okkenhaug K, Carrera AC, Barber DF.

PLoS One. 2013 Aug 29;8(8):e72960. doi: 10.1371/journal.pone.0072960. eCollection 2013.

38.

A protocol for construction of gene targeting vectors and generation of homologous recombinant embryonic stem cells.

Bouabe H, Okkenhaug K.

Methods Mol Biol. 2013;1064:337-54. doi: 10.1007/978-1-62703-601-6_24.

39.

Gene targeting in mice: a review.

Bouabe H, Okkenhaug K.

Methods Mol Biol. 2013;1064:315-36. doi: 10.1007/978-1-62703-601-6_23. Review.

40.

Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity.

Okkenhaug K.

Ann N Y Acad Sci. 2013 Mar;1280:24-6. doi: 10.1111/nyas.12027.

41.

Signaling by the phosphoinositide 3-kinase family in immune cells.

Okkenhaug K.

Annu Rev Immunol. 2013;31:675-704. doi: 10.1146/annurev-immunol-032712-095946. Epub 2013 Jan 16. Review.

42.

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.

Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K, Cantrell DA.

J Exp Med. 2012 Dec 17;209(13):2441-53. doi: 10.1084/jem.20112607. Epub 2012 Nov 26.

43.

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.

Banham-Hall E, Clatworthy MR, Okkenhaug K.

Open Rheumatol J. 2012;6:245-58. doi: 10.2174/1874312901206010245. Epub 2012 Sep 7.

44.

Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.

Roller A, Perino A, Dapavo P, Soro E, Okkenhaug K, Hirsch E, Ji H.

J Immunol. 2012 Nov 1;189(9):4612-20. doi: 10.4049/jimmunol.1103173. Epub 2012 Sep 28.

45.

Does the PI3K pathway promote or antagonize regulatory T cell development and function?

Soond DR, Slack EC, Garden OA, Patton DT, Okkenhaug K.

Front Immunol. 2012 Aug 14;3:244. doi: 10.3389/fimmu.2012.00244. eCollection 2012.

46.

Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.

Soond DR, Garçon F, Patton DT, Rolf J, Turner M, Scudamore C, Garden OA, Okkenhaug K.

J Immunol. 2012 Jun 15;188(12):5935-43. doi: 10.4049/jimmunol.1102116. Epub 2012 May 18.

47.

Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.

Ying H, Fu H, Rose ML, McCormack AM, Sarathchandra P, Okkenhaug K, Marelli-Berg FM.

PLoS One. 2012;7(3):e32892. doi: 10.1371/journal.pone.0032892. Epub 2012 Mar 30.

48.

PI3Kβ plays a critical role in neutrophil activation by immune complexes.

Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, Hirose M, Juss J, Oxley D, Chessa TA, Ramadani F, Guillou H, Segonds-Pichon A, Fritsch A, Jarvis GE, Okkenhaug K, Ludwig R, Zillikens D, Mocsai A, Vanhaesebroeck B, Stephens LR, Hawkins PT.

Sci Signal. 2011 Apr 12;4(168):ra23. doi: 10.1126/scisignal.2001617.

49.

The PI3K p110δ regulates expression of CD38 on regulatory T cells.

Patton DT, Wilson MD, Rowan WC, Soond DR, Okkenhaug K.

PLoS One. 2011 Mar 1;6(3):e17359. doi: 10.1371/journal.pone.0017359.

50.

Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.

Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, Feijoo C, Okkenhaug K, Cantrell DA.

Immunity. 2011 Feb 25;34(2):224-36. doi: 10.1016/j.immuni.2011.01.012. Epub 2011 Feb 3.

Supplemental Content

Loading ...
Support Center